Education
About Us
Working with TipRanks
Follow Us
Structure Therapeutics, Inc. Sponsored ADR (GPCR)
NASDAQ:GPCR
GPCR Stock Chart & Stats
$34.22
-$0.32(-1.18%)
At close: 4:00 PM EST
$34.22
-$0.32(-1.18%)
Day’s Range― - ―
52-Week Range$13.22 - $40.29
Previous CloseN/A
Volume219.80K
Average Volume (3M)1.08M
Market Cap
$2.08B
Enterprise Value$845.76M
Total Cash (Recent Filing)$799.04M
Total Debt (Recent Filing)$7.09M
Price to Earnings (P/E)―
Beta1.34
Next Earnings
Mar 26, 2026EPS Estimate
-0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.37
Shares Outstanding60,677,640
10 Day Avg. Volume1,656,634
30 Day Avg. Volume1,081,607
Financial Highlights & Ratios
PEG Ratio3.15
Price to Book (P/B)1.65
Price to Sales (P/S)0.00
P/FCF Ratio-12.11
Enterprise Value/Market Cap0.41
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.23K
Enterprise Value/Ebitda-3.55
Forecast
1Y Price Target
$74.00Price Target Upside116.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-1.39
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial HealthStructure has a strong balance sheet with $800M in cash, expected to fund operations for over three years.
Market PositionStructure's approach to a 'start low, go slow' titration in the Phase 2b ACCESS studies is expected to improve aleniglipron's tolerability profile, aligning with positive outcomes seen in competitor trials.
Product DevelopmentStructure is guiding on initiation of a first-in-human trial for lead amylin agonist by YE 2025, marking significant progress in their development pipeline.
Bears Say
Clinical Trial RisksThe bear case presents a risk of a 30–70% downside if aleniglipron shows near 10% efficacy with worse tolerability or a clear miss with 10% discontinuations.
Market Reaction RisksRecent obesity data for a similar drug, orfoglipron, received poorly by investors, highlighting the risk of market reactions to clinical trial outcomes.
Participant Retention ChallengesApproximately 25% of participants discontinued the study for any reason across all arms, indicating some challenges with participant retention.
Structure Therapeutics, Inc. Sponsored ADR News
GPCR FAQ
What was Structure Therapeutics, Inc. Sponsored ADR’s price range in the past 12 months?
Structure Therapeutics, Inc. Sponsored ADR lowest stock price was $13.22 and its highest was $40.29 in the past 12 months.
What is Structure Therapeutics, Inc. Sponsored ADR’s market cap?
Structure Therapeutics, Inc. Sponsored ADR’s market cap is $2.08B.
When is Structure Therapeutics, Inc. Sponsored ADR’s upcoming earnings report date?
Structure Therapeutics, Inc. Sponsored ADR’s upcoming earnings report date is Mar 26, 2026 which is in 116 days.
How were Structure Therapeutics, Inc. Sponsored ADR’s earnings last quarter?
Structure Therapeutics, Inc. Sponsored ADR released its earnings results on Nov 06, 2025. The company reported -$0.37 earnings per share for the quarter, missing the consensus estimate of -$0.365 by -$0.005.
Is Structure Therapeutics, Inc. Sponsored ADR overvalued?
According to Wall Street analysts Structure Therapeutics, Inc. Sponsored ADR’s price is currently Undervalued.
Does Structure Therapeutics, Inc. Sponsored ADR pay dividends?
Structure Therapeutics, Inc. Sponsored ADR does not currently pay dividends.
What is Structure Therapeutics, Inc. Sponsored ADR’s EPS estimate?
Structure Therapeutics, Inc. Sponsored ADR’s EPS estimate is -0.39.
How many shares outstanding does Structure Therapeutics, Inc. Sponsored ADR have?
Structure Therapeutics, Inc. Sponsored ADR has 60,677,640 shares outstanding.
What happened to Structure Therapeutics, Inc. Sponsored ADR’s price movement after its last earnings report?
Structure Therapeutics, Inc. Sponsored ADR reported an EPS of -$0.37 in its last earnings report, missing expectations of -$0.365. Following the earnings report the stock price went down -1.882%.
Which hedge fund is a major shareholder of Structure Therapeutics, Inc. Sponsored ADR?
Currently, no hedge funds are holding shares in GPCR
Structure Therapeutics, Inc. Sponsored ADR Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$74.00 (116.25% Upside)
$74.00 (116.25% Upside)
Blogger Sentiment
Bullish
GPCR Sentiment 66%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 814.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.0%
Last 30 Days ▲ 0.4%
Last 30 Days ▲ 0.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
1.42%
12-Months-Change
Fundamentals
Return on Equity
-25.31%
Trailing 12-Months
Asset Growth
-10.83%
Trailing 12-Months
Company Description
Structure Therapeutics, Inc. Sponsored ADR
Structure Therapeutics, Inc. Sponsored ADR (GPCR) is a biopharmaceutical company focused on discovering and developing innovative treatments for patients with unmet medical needs. The company primarily operates within the healthcare sector, specializing in the development of novel drug candidates targeting G protein-coupled receptors (GPCRs), which play a crucial role in various physiological processes and diseases. Structure Therapeutics leverages advanced technologies and scientific expertise to design and develop therapeutic compounds aimed at addressing conditions such as metabolic disorders, inflammation, and other significant health challenges.
GPCR Stock 12 Month Forecast
Average Price Target
$74.00
▲(116.25% Upside)
Technical Analysis
Ownership Overview
11.29% Insiders
23.45% Mutual Funds
48.75% Other Institutional Investors
15.48% Public Companies and Individual Investors